Terms: = Colorectal cancer AND SMAD3, JV15-2, 4088, ENSG00000166949, P84022, Smad3, MADH3, HsT17436, Smad 3, DKFZp686J10186, HSPC193, DKFZP586N0721, MGC60396 AND Diagnosis
11 results:
1. OLFM2 promotes epithelial-mesenchymal transition, migration, and invasion in colorectal cancer through the TGF-β/smad signaling pathway.
Tang Y; Liu Y; Wang X; Guo H; Chen L; Hu G; Cui Y; Liang S; Zuo J; Luo Z; Chen X; Wang X
BMC Cancer; 2024 Feb; 24(1):204. PubMed ID: 38350902
[TBL] [Abstract] [Full Text] [Related]
2. Long-read sequencing identifies novel structural variations in colorectal cancer.
Xu L; Wang X; Lu X; Liang F; Liu Z; Zhang H; Li X; Tian S; Wang L; Wang Z
PLoS Genet; 2023 Feb; 19(2):e1010514. PubMed ID: 36812239
[TBL] [Abstract] [Full Text] [Related]
3. Prolyl 4-hydroxylase subunit alpha 3 facilitates human colon cancer growth and metastasis through the TGF-β/smad signaling pathway.
Zhou H; Zou J; Shao C; Zhou A; Yu J; Chen S; Xu C
Pathol Res Pract; 2022 Feb; 230():153749. PubMed ID: 34959098
[TBL] [Abstract] [Full Text] [Related]
4. FSTL1 interacts with VIM and promotes colorectal cancer metastasis via activating the focal adhesion signalling pathway.
Gu C; Wang X; Long T; Wang X; Zhong Y; Ma Y; Hu Z; Li Z
Cell Death Dis; 2018 May; 9(6):654. PubMed ID: 29844309
[TBL] [Abstract] [Full Text] [Related]
5. The TGF-β pathway is activated by 5-fluorouracil treatment in drug resistant colorectal carcinoma cells.
Romano G; Santi L; Bianco MR; Giuffrè MR; Pettinato M; Bugarin C; Garanzini C; Savarese L; Leoni S; Cerrito MG; Leone BE; Gaipa G; Grassilli E; Papa M; Lavitrano M; Giovannoni R
Oncotarget; 2016 Apr; 7(16):22077-91. PubMed ID: 26956045
[TBL] [Abstract] [Full Text] [Related]
6. [microRNA-140 suppresses the migration and invasion of colorectal cancer cells through targeting smad3].
Zhao W; Zou J; Wang B; Fan P; Mao J; Li J; Liu H; Xiao J; Ma W; Wang M; Li L; Song B
Zhonghua Zhong Liu Za Zhi; 2014 Oct; 36(10):739-45. PubMed ID: 25567303
[TBL] [Abstract] [Full Text] [Related]
7. The influence of the CHIEF pathway on colorectal cancer-specific mortality.
Slattery ML; Lundgreen A
PLoS One; 2014; 9(12):e116169. PubMed ID: 25541970
[TBL] [Abstract] [Full Text] [Related]
8. Small can be beautiful: 10 years managing colorectal cancer in a rural general hospital.
Grant AJ; Sedgwick DM
Scott Med J; 2011 Feb; 56(1):26-9. PubMed ID: 21515529
[TBL] [Abstract] [Full Text] [Related]
9. Genetic variation in the transforming growth factor-β signaling pathway and survival after diagnosis with colon and rectal cancer.
Slattery ML; Lundgreen A; Herrick JS; Wolff RK; Caan BJ
Cancer; 2011 Sep; 117(18):4175-83. PubMed ID: 21365634
[TBL] [Abstract] [Full Text] [Related]
10. Genetic variation in the TGF-β signaling pathway and colon and rectal cancer risk.
Slattery ML; Herrick JS; Lundgreen A; Wolff RK
Cancer Epidemiol Biomarkers Prev; 2011 Jan; 20(1):57-69. PubMed ID: 21068203
[TBL] [Abstract] [Full Text] [Related]
11. The androgen receptor CAG repeat: a modifier of carcinogenesis?
Ferro P; Catalano MG; Dell'Eva R; Fortunati N; Pfeffer U
Mol Cell Endocrinol; 2002 Jul; 193(1-2):109-20. PubMed ID: 12161010
[TBL] [Abstract] [Full Text] [Related]
